Lack of nephrotoxicity of intravenous dimethylsulfoxide.
Intravenous dimethylsulfoxide (DMSO) was used to treat seven patients with stable spinal cord injuries. Because of drug-associated hemoglobinemia and hemoglobinuria, the patients were studied for subtle evidence of renal tubular dysfunction by serial measurements of urinary beta-2-microglobulin excretion. No increases in tubular protein excretion or decreases in glomerular filtration rate were observed following short-term infusions of 10-40% DMSO. It is concluded that there is no significant short-term nephrotoxicity from intravenous DMSO.
D000293:Adolescent; D000328:Adult; D004121:Dimethyl Sulfoxide / Q000009:adverse effects*; D005260:Female; D006456:Hemoglobinuria / Q000139:chemically induced; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D008297:Male; D001613:beta 2-Microglobulin / Q000652:urine
D001613:beta 2-Microglobulin; D004121:Dimethyl Sulfoxide